US EditionDo LRRK2 Heterobifunctional Degraders Mitigate “On-Target” Toxicity?
Summary by Drug Hunter
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Do LRRK2 Heterobifunctional Degraders Mitigate “On-Target” Toxicity?
LRRK2 kinase inhibitors promised to revolutionize Parkinson’s disease therapy—until preclinical lung toxicity, believed to be on-target, halted their progress. Heterobifunctional degraders now offer a fresh approach. By fully degrading the LRRK2 protein these molecules demonstrate enhanced efficacy. Additionally, initial results show the potential avoidance of the lung fibrosis seen with kinase inhibitors. This review provides a brief history of…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium